Navigation Links
Phase II study of an oral therapy for Gaucher disease yields positive results
Date:5/3/2010

re hoping an oral alternative would be viable," said lead study author Elena Lukina, MD, of the Hematology Research Center at the Russian Academy of Medical Sciences in Moscow, Russia.

The study endpoint (improvement in at least two of the three main efficacy parameters: spleen volume, hemoglobin level, and platelet count) was met by three-fourths (77%) of all patients and nearly all (91%) of the 22 patients who completed the full 52 weeks, with the greatest overall improvements seen in hemoglobin level and spleen volume. The research team found statistically significant improvements across many disease symptoms, including mean hemoglobin level, platelet count, spleen volume, liver volume, and lumbar spine bone mineral density. Furthermore, the patients' glucosylceramide plasma levels normalized. Disease symptoms seemed to respond rapidly, and improvement was seen especially in bone mineral density. This may have resulted from the drug's small molecular size, which allows it to diffuse quickly within affected cells.

"Eliglustat tartrate provides promise for a safe, effective, and convenient oral therapy for patients with Gaucher disease type 1," said Dr. Lukina.

Further clinical development of eliglustat tartrate is already proceeding with larger, controlled Phase III studies in untreated patients and in patients previously stabilized with imiglucerase an intravenously administered medication currently used to treat Gaucher disease.


'/>"/>

Contact: Wendy Stokes
webmaster@hematology.org
202-776-0544
American Society of Hematology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
2. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
3. Southampton scientists begin Phase II patient trial for new asthma treatment
4. Intellicate Announces New “Phased Return to Work” (PRtW) Service
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
7. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
8. New High Purity Immunoglobulin Enters Phase III in Europe and the US
9. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
10. NASA selects DNA Medicine Institutes Nanoscale Diagnostics Technology for Phase II SBIR
11. PRA International Rolls out Client Access to Oracle(R) RDC for Early Phase Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... of conventional in vitro fertilization (IVF) -- the incubation of ... in a device inside the vagina, new research suggests. ... device, called an INVOcell, might sharply cut costs for pricey ... technology more accessible to those who don,t live near big-city ...
(Date:10/20/2014)... Florida (PRWEB) October 20, 2014 With ... former Gov. Charlie Crist made a brief fundraising stop ... Orlando on Thursday. , Fresh from a debate last ... to take the stage for the first seven minutes ... the former governor described the incident in one word: ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 T.E.N., ... relationship-marketing firm, announced today that William H. Murray, ... the 2014 ISE® Luminary Leadership Award winner. Presented ... achievements of an outstanding leader and industry practitioner ... contributions in advancing the information security industry. , ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... study in the Aug. 1 issue of the journal Sleep ... infants are easier to arouse than females during quiet sleep, and ... gender differences in arousability. The results suggest that the increased ... reflect a pre-existing vulnerability involving arousal responses. Results show that ...
... Teenage years have long been linked with a heightened ... and tout happiness as just a nip/tuck away. A RutgersCamden ... programs are more likely to join the millions who go ... - still in development, these drastic decisions could have implications ...
... LANSING, Mich. - With the help of a $2.5 ... State University is creating a cross-discipline, mentored program designed ... women,s health., MSU,s new Building Interdisciplinary Research Careers in ... of Medicine in the College of Human Medicine, will ...
... strain, ST131, was a major cause of serious antimicrobial-resistant ... researchers found. This strain has been reported in multiple countries ... study, researchers analyzed resistant E. coli isolates collected ... 54 ST131 isolates, which accounted for 67 percent to 69 ...
... CD74 is a protein that is expressed in and ... lymphocytes and antigen presenting cells. This protein is known ... immune response. Additionally, Professor Shachar,s lab has previously shown ... of the immune system, and that its stimulation by ...
... refers to a group of disorders characterized by ... bile ducts. Multiple causes have been identified including ... medications. The usual course of this condition is ... treatment of the underlying condition and/ or removal ...
Cached Medicine News:Health News:SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls 2Health News:SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls 3Health News:Reality TV, cosmetic surgey linked, says Rutgers-Camden researcher 2Health News:MSU targets women's health research with $2.5 million grant 2Health News:Vanishing bile duct syndrome secondary to anti-retroviral therapy in HIV 2
(Date:10/22/2014)... , Oct. 22, 2014  Rescheduling of hydrocodone ... in the pain market, according to a new ... a firm providing market research and consultation exclusively ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... for hydrocodone combination products from Schedule III to ...
(Date:10/22/2014)... , October 22, 2014 Investor-Edge ... Inc. (NASDAQ: FOLD ), Progenics Pharmaceuticals Inc. ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... 21, 2014, the NASDAQ Composite ended at 4,419.48, up ...
(Date:10/22/2014)... , Oct. 22, 2014  Charlene Vernak, RPh, of ... , recently was awarded the George Roentsch Scholarship ... received the award in Houston ... scholarship is awarded annually to an independent pharmacist and ... of George Roentsch , a well-known pharmacist in ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2
For the rapid determination of human chorionic gonadotropin (hCG) in urine. The test strip is used to obtain a visual qualitative result....
... GE Healthcares new Vivid i ... cardiovascular ultrasound system to provide high-performance, full-featured ... Vivid i addresses one ... access to complete, real-time diagnostic information. ...
... is an immunochromatographic in vitro assay for ... in human serum or plasma. Elevated concentration ... pathologies. It may also be caused by ... of IgE using InstaTest IgE test kit ...
... Through its unique and patented ... wires and trunk cables between patients ... monitors, allowing freedom of movement throughout ... technology, the LifeSync(R) System employs two-way ...
Medicine Products: